Dendritic cell vaccines
US9862927B2 · kind B2 · utility
7Cited by
2References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 21, 2011 |
| Grant date | Jan 9, 2018 |
| Priority date | — |
| Expiry date | Mar 13, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16334
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.